Surlorian not checked

RyCarma Therapeutics, Inc. · S48168 · ARM 210

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
1 active
3 in total · 1 in the EU

What this is

How it works
How it works isn't classified yet
Tested for
Autosomal Dominant RYR1-Related Myopathy
Main trialPhase 2
“This study is testing a medicine called surlorian in adults who have a genetic muscle condition known as autosomal dominant RYR1-related myopathy (RYR1-RM). The goal is to find out whether surlorian improves muscle weakness, and whether it is safe and well tolerated.”In the company’s words, NCT07560020 on ClinicalTrials.gov
Other names
S48168 · ARM 210

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials3

TrialPhaseCompletesWhat it tests
Phase 2Recruiting 27 Aug 2027 A Trial to Compare Treatment With Surlorian (ARM210, S48168) to Placebo in Effects on Muscle Strength and Safety in Adults With Autosomal Dominant RYR1-related Myopathy
Phase 2Terminated 1 Apr 2024 Treatment of an Inherited Ventricular Arrhythmia
Phase 1Completed 30 Dec 2022 S 48168 (ARM 210) for the Treatment of RYR1-related Myopathies (RYR1-RM)
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow Surlorian

Following is part of Solo: you see every change to Surlorian the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in